BNA’s Health Care Daily Report™ sets the standard for reliable, high-intensity coverage of breaking health care news, covering all major legal, policy, industry, and consumer developments in a...
By Nathaniel Weixel
Medicare is spending too much money erroneously reimbursing claims for antipsychotic drugs, officials from the Centers for Medicare & Medicaid Services and the Department of Health and Human Services Office of Inspector General Nov. 30 told a Senate panel, and more needs to be done to stop physicians from prescribing them.
OIG Inspector General Daniel Levinson told the Senate Special Committee on Aging that all too often, nursing home patients receive antipsychotic drugs in ways that violate federal standards designed to prevent overmedication and inappropriate use.
According to Levinson, atypical antipsychotic drugs are intended for the treatment of psychoses and mood disorders. Physicians are not prevented from prescribing these drugs, either for approved indications or for off-label uses, even if they might carry a high risk to a patient's health.
“When properly prescribed, antipsychotics can offer beneficial treatment for individuals suffering from mental illness,” the panel's chairman, Sen. Herb Kohl (D-Wis.), said. “However, we have a responsibility to patients and their families to ensure that elderly nursing home residents are free from all types of unnecessary drugs, and we have a responsibility to taxpayers to be certain that they are not paying for drugs that are not needed.”
Levinson cited a report OIG released in May that found that 83 percent of all reviewed Medicare atypical antipsychotic drug claims for elderly nursing home residents were for off-label uses (91 HCDR, 5/11/11).
According to the report, from Jan. 1 through June 30, 2007, 51 percent of the Medicare reimbursement claims for atypical antipsychotic drugs were also erroneous, and they cost the program $116 million. Medicare Part D requires that drugs must be prescribed for “medically accepted indications” to qualify for reimbursement.
OIG in the report recommended that CMS could require nursing homes to reimburse the Part D program when claimed drugs violated quality and safety standards.
Levinson also cited a more recent report, posted Nov. 14, which found that Part D prescription drug plan (PDP) sponsors lack access to the information necessary to ensure appropriate reimbursement of Part D drugs, including antipsychotics (221 HCDR, 11/16/11).
Medicare is paying for drugs that it should not, and Part D prescription drug plans are not able to adequately prevent inappropriate payments for drugs, including antipsychotics, for uses that do not meet coverage requirements, Levinson said. In addition, nursing homes often fail to comply with regulations designed to prevent overmedication of these powerful and at times dangerous drugs, he said.
Levinson said the report also found that the PDP sponsors do not routinely collect diagnosis information, except when using prior authorization. The PDP sponsors indicated that prior authorization is the best tool they have to compare the diagnosis provided by the prescriber to the medically accepted indications contained in the compendia.
However, Levinson said, CMS disagreed that the solution to inappropriate drug use lies with the PDP sponsors' utilization management tools, including prior authorization.
Patrick Conway, CMS chief medical officer and director for the Office of Clinical Standards and Quality, told the panel that CMS and OIG have a shared goal of encouraging appropriate prescribing by nursing home physicians.
Conway said that although the off-label prescribing of antipsychotic drugs for treatment of dementia is a complex problem, it can be solved.
A solution “will need collaborative quality improvement, and emphasis on nonpharmacological options to treat dementia and behavioral disturbances in patients with dementia,” Conway said.
He said CMS is continuing to explore new ways to strengthen enforcement of current rules by eliminating conflicts of interest that may influence prescribing and better educating providers, prescribers, and patients' families to eliminate inappropriate prescribing.
“Improper prescribing not only puts patients' health at risk; it also leads to higher costs,” Kohl said. “We can do better.”
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)